despite the fact NT-proBNP is not degraded through natriuretic peptide clearance receptors-C. A more likely explanation for the lower levels in patients with obesity is suggested by Bartels et al. 7 They hypothesize that the expression of BNP is impaired in patients with obesity because of lipid accumulation, suggesting a link between the fat metabolism and BNP expression. Lower circulating levels have led to the suggestion that different cutoff points should be used in patients with obesity. 8 With the rising prevalence of obesity worldwide, HF in patients with obesity is a growing problem. In contrast to BNP, to date, it is unknown how other (cardiac) biomarkers behave across the BMI spectrum. Little is known about a variety of clinical used markers such as troponin or more novel marker for HF such as galectin-3 or growth differentiation factor 15. The association between BMI and these markers could influence their interpretation in patients with a higher BMI in contrast to patients with a lower BMI.
Therefore, we aimed to study biomarker levels in patients with obesity with acute HF and their behavioral patterns across the BMI spectrum.
Methods

Study Population
The study population consisted of 2033 patients originating from the PROTECT trial (Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function), which had neutral results. [9] [10] [11] The local ethics committee at each participating center approved the trial, and all patients provided written informed consent. Key inclusion criteria were dyspnea at rest or at minimal exertion, BNP level ≥500 pg/mL or NT-proBNP ≥2000 pg/mL, and a creatinine clearance between 20 and 80 mL/min. Other inclusion and exclusion criteria are outlined in the design paper. A total of 48 biomarkers were determined and fully available in 1266 patients. Patients included in the PROTECT trial with weight and height measurements available were included in the analysis. In total, 2003 patients had weight and height available at day 1, and 1742 patients had known weight and height at day 4.
The patients with known height and weight at admission were separated in 4 different groups based on BMI (weight [ 
Study Procedures
In total, 48 biomarkers were evaluated at baseline. Many markers (albumin, alanine transaminase, aspartate transaminase, bicarbonate, blood urea nitrogen, chloride, creatinine, glucose, hemoglobin, platelet count, potassium, red blood cell count, sodium, total cholesterol, triglycerides, uric acid, and white blood cell count) were determined in ICON Laboratories, Farmingdale, NY. The following 26 biomarkers were assessed by Alere Inc., San Diego, CA. Using ELISA galectin-3, myeloperoxidase, and neutrophil gelatinaseassociated lipocalin (NGAL) were measured. By using competitive ELISAs on a Luminex platform angiogenin and C-reactive protein were measured. By using sandwich ELISAs on a Luminex platform D-dimer, endothelial cell-selective adhesion molecule, growth differentiation factor 15, lymphotoxin beta receptor, mesothelin, neuropilin, N-terminal pro-C-type natriuretic peptide, osteopontin, procalcitonin, pentraxin-3, periostin, polymeric immunoglobulin receptor, proadrenomedullin, prosaposin B, receptor for advanced glycation endproducts (RAGE), soluble ST-2, syndecan-1, tumor necrosis factor-α receptor 1, Troy, vascular endothelial growth receptor 1, and WAP 4-disulphide core domain protein HE4 were determined. An extra 5 biomarkers, BNP (endothelin-1, interleukin-6, kidney injury molecule, and cardiac troponin I were assessed by single-molecule counting technology by Erenna Immunoassay System on a microtiter plate by Singulex Inc., Alameda, CA. Immunoassays to procalcitonin, proadrenomedullin, galectin-3, and ST2 were developed by Alere. These research assays have not been standardized to the commercialized assays used in research or in clinical use and the extent to which each Alere assay correlates with the commercial assay is not fully characterized. Additional information about the assays are presented in Table I in the Data Supplement.
Statistical Analysis
Normally distributed data are presented as means and SD, skewed data as medians and 25th to 75th percentiles, and categorical variables as percentages and frequencies. Intergroup differences between variables were tested using one-way ANOVA for normally distributed data; skewed data were tested using χ 2 test or Kruskal-Wallis test depending on whether the data were continuous or nominal. With multivariable fractional polynomials best fit for each variable was estimated.
To assess predictors of a higher BMI, multivariable linear regression models were constructed. A natural logarithmic transformation of BMI was used (Log BMI). Variables that might correlate with each other were alternated in multivariable analysis. Before entering the variables in the model, variables were standardized by dividing them by their SD. Backward and stepwise multivariable analyses were used. The final model with backward analysis consisted of biomarkers, demographics, medical history, and previous medication. Proportional hazards survival (Cox proportional hazard analysis) was used to estimate the effect of BMI on mortality up to 180 days and the effect of biomarker levels on mortality up to 180 days. In multivariable models to estimate the effect of BMI, adjustments were made for age and sex. In Cox proportional hazard analysis for biomarker levels, adjustments were made for age, sex, and Log BMI.
Kaplan-Meier curves were assessed to estimate the effect of BMI on mortality up to 180 days. Differences in survival rates between the different BMI groups were tested using the log-rank test (MantelCox test). Forest plots were drafted to evaluate the predictive value and hazard ratio of mortality up to 180 days between a BMI <30 kg/ m 2 and >30 kg/m 2 put out against 7 biomarkers. A 2-sided P <0.05 was considered statistically significant.
All analyses were performed using IBM SPSS Statistics version 22 and R: a Language and Environment for Statistical Computing, 
Results
Baseline Characteristics
Baseline characteristics for all 2003 patients were divided according to BMI groups. Baseline characteristics are shown in Table 1 . Mean age for the total cohort is 70±12 years, with predominantly male patients (67%). Almost half of the patients had New York Heart Association class III (n=965). The mean left ventricular ejection fraction in the total cohort was 32±13%. In patients with a BMI >35 kg/m 2 , 89% (n=254) had a history of hypertension and 62% (n=178) had a history of diabetes mellitus. Despite these risk factors, patients with obesity were less likely to have ischemic heart disease or myocardial infarction when compared with patients in lower BMI groups. Patients with a higher BMI were younger, were less frequently men, and had higher systolic and diastolic blood pressures and higher heart rate. Biomarkers and Obesity in AHF
Biomarkers at Baseline
All biomarkers at baseline are shown in Table 2 . A higher BMI is associated with a lower BNP and a higher galectin-3 (P<0.001). Glucose levels are higher in patients with a BMI between 25 and 30 kg/m 2 and patients with a BMI between 30 and 35 kg/m 2 . The same applies to creatinine (P<0.001), plasma NGAL (P<0.001), uric acid (P<0.001), and sodium (P<0.001). Widely used markers such as troponin-I, C-reactive protein, and interleukin-6 do not differ. Because BMI is determined by weight, patients with more edema could have had a higher BMI. The same statistics were performed with weight on day 4, in a more recompensated state. Data did not significantly differ in outcome (Table II in the Data Supplement). To check for informed censoring, a baseline table was drafted based on all biomarkers available or not all biomarkers available. Data did not substantially differ (Table III in 
Correlates for BMI
In univariable and multivariable linear regression analyses, clinical correlates for BMI are assessed and are shown in Table 3 . A lower age (β=−0.035; P<0.001), a higher diastolic blood pressure (β=0.023; P=0.001), a medical history of diabetes mellitus (β=0.104; P<0.001), and hypertension (β=0.085; P=0.001) are associated with a higher BMI. Univariable regression analyses is shown in Table IV in the Data Supplement. BNP (β=−0.051; P<0.001) and RAGE (β=−0.020; P<0.007) are inversely correlated to BMI. Uric acid (β=0.032; P<0.001), proadrenomedullin (β=0.034; P<0.001), creatinine (β=0.023; P=0.003), sodium (β=0.021; P=0.006), and bicarbonate (β=0.020; P=0.009) are positively correlated with BMI in a multivariable model. Statistics were also performed on these 7 biomarkers using weight at day 4, which did not significantly alter our findings (Table V in 
BMI and Mortality Up To 180 Days
Cox proportional hazard regression models for BMI predicting mortality up to 180 days are presented in Table 4 . In univariable analysis, a higher BMI is associated with lower mortality rates (hazard ratio 0.53; P=0.019). However, in a multivariable model after adjustment for sex and age, there is no longer a significant association between BMI and mortality up to 180 days (hazard ratio 0.69; P=0. 21) . Figure 1 shows the Kaplan-Meier curve for survival up to 180 days. Whereas the lowest survival rates are in the group with a BMI <25 kg/ m 2 (80%), and the best survival is seen in the group with a BMI 30 to 35 kg/m 2 (86.1%); there is no significant difference between the groups (P=0.087).
To evaluate the predictive value of biomarkers in relation to mortality for a BMI above and below 30 kg/m 2 , Forest plots were drafted (Figure 2 ). Within these plots, 7 biomarkers associated with BMI were separated into a BMI above or below 30 Values are given as means±SD, median (25th to 75th percentiles) or percentage and frequency. BMI indicates body mass index; LVEF, left ventricular ejection fraction; and NYHA, New York Heart Association. . There is no significant interaction between BMI and any of the biomarkers.
Discussion
In a wide spectrum of biomarkers, measured in a large group of patients with acute HF, we show several biomarkers to be either positively (proadrenomedullin, uric acid, creatinine, sodium, and bicarbonate) or negatively (BNP and RAGE) correlated with BMI. The prognostic value of the biomarkers for mortality up to 180 days was similar in patients with lower and higher BMI.
Cardiac Biomarkers and Obesity
Previous studies have already showed that a higher BMI is associated with lower serum BNP levels, but despite these findings, there is still no consensus about the underlying mechanism. A possible hypothesis is thought to be that the expression of BNP is impaired in patients with obesity because of lipid accumulation, suggesting a link between the fat metabolism and BNP expression. This could be because of the fact that triglyceride accumulation in the heart could lead to cellular stress and apoptosis. BNP induces lipolysis in adipocytes and might reduce the release of free fatty acids and its adverse effects. 7 Circulating levels of BNP were also strongly negatively related to patients with acute HF and a high BMI in our study. The negative correlation between BMI and BNP is found in not only patients with HF but also healthy patients. 12 Our data confirm a negative relation between BMI and BNP, which influences the clinical interpretation of circulating BNP levels. Out of the 7 markers stated to be associated with BMI, BNP seems to be most strongly correlated with BMI. Christensen et al 13 found in patients with chronic HF that only NP and adiponectin were associated with BMI. However, they reviewed 7 biomarkers in contrast to our 48 biomarkers, and in patients with chronic HF while our database consists of patients with acute HF.
Noncardiac Biomarkers and Obesity
One of the biomarkers in our study which is strongly correlated to a high BMI is uric acid. Recent studies provided a couple of reasons why uric acid is elevated in patients with obesity. Uric acid is the product of the purine metabolism. Purines are mainly found in red meat or shellfish. One of the possible reasons patients with obesity might have higher circulating levels of uric acid is because of a higher intake of purines.
14 Furthermore, adipose tissue is known to secrete uric acid. Obesity creates more mRNA expression and activity of the xanthine oxidoreductase, which converts xanthine into uric acid, resulting in increased levels of uric acid. 15, 16 High uric acid levels are known to play a role in the development of metabolic syndrome, a clustering of abdominal obesity, insulin resistance, dyslipidemia, and elevated blood pressures, all cardiovascular Values are given as means±SD, median (25th to 75th percentiles) or percentage and frequency. Alt indicates alanine transaminase; Ast, aspartate transaminase, BMI, body mass index; BNP, brain natriuretic peptide; CRP, C-reactive protein; ESAM, endothelial cell-selective adhesion molecule; GDF, growth differentiation factor 15; KIM-1, kidney injury molecule 1; LTBR, lymphotoxin β receptor; NGAL, neutrophil gelatinase-associated lipocalin; NT-pro-CNP, N-terminal pro C-type natriuretic peptide; PIGR, polymeric immunoglobulin receptor; pro-ADM, proadrenomedullin; PSAB-B, prosaposin B; RAGE, receptor for advanced glycation endproducts; RBC, red blood cell count; VEGFR, vascular endothelial growth receptor 1; WAP4C, WAP four-disulphide core domain protein HE4; and WBC, white blood cell count. All univariable significant variables (P<0.1) where entered in a multivariable backward model. Only one measurement of blood pressure (systolic/diastolic) and renal function (creatinine, creatinine clearance, and neutrophil gelatinaseassociated lipocalin) was entered because of collinearity.
Adjusted R 2 = 0.276. BMI indicates body mass index; BNP, brain natriuretic peptide; CI, confidence interval; DM, diabetes mellitus; pro-ADM, proadrenomedullin; and RAGE, receptor for advanced glycation endproducts. risk factors. 17 Of note, we observed more hypertension and diabetes mellitus in our patients with obesity although less ischemic heart disease and myocardial infarction.
Higher levels of serum bicarbonate are also correlated with a higher BMI. Bicarbonate is more often raised in patients with acute HF, which is linked to the use of diuretics. Depending on the choice of diuretics, they often give electrolyte and acid disorders. Changes in potassium, sodium, uric acid, and bicarbonate are not uncommon. 18 Furthermore, studies have shown that bicarbonate is associated with worsening renal function, more HF events, and higher mortality. 18, 19 A possible explanation for the correlation between a higher BMI and bicarbonate might be that a higher serum bicarbonate is associated with obesity hypoventilation syndrome. Because of chronic hypoventilation in patients with obesity, bicarbonate raises in reaction to hypercapnia. 20 Another biomarker strongly associated with a high BMI in our study is proadrenomedullin, a precursor for adrenomedullin. Adrenomedullin is a vasodilator peptide, synthesized by a variety of tissues, for example, heart, lungs, and kidney. Most important function of adrenomedullin in cardiovascular diseases seems to be its effects against oxidative stress. 21 This biomarker has recently been described as strong predictor for all-cause mortality. 22, 23 Proadrenomedullin is often raised in patients with obesity because adipose tissue contains receptor activity modifying proteins that together form the adrenomedullin receptor. The increased number of receptors is thought to protect against complications of comorbidities in obesity, like diabetes mellitus and hypertension, through vasodilatation. 24 Furthermore, several renal biomarkers were evaluated, including plasma kidney injury molecule-1 and NGAL, which are both markers of tubular damage. 25 Both plasma kidney injury molecule-1 and plasma NGAL are higher in higher BMI groups. These higher levels of plasma kidney injury molecule-1 and plasma NGAL suggest tubular damage in patients with a higher BMI. Despite the higher creatinine clearance found in this study, these findings suggest that the renal function in patients with obesity is worse compared with nonobese groups. Patients with obesity are more often affected by a variety of comorbidities, such as diabetes mellitus and higher blood pressures. These factors could explain the decreased renal function in patients with obesity.
RAGE is expressed in the heart in cardiomyocytes, fibroblasts, and inflammatory cells and is released after cardiomyocyte injury. Serum levels of this receptor could therefore reflect the degree of HF. 26 However, the predictive value of RAGE is not yet fully established. 27, 28 Although vascular cells express RAGE, this contributes to soluble forms of RAGE. These soluble forms of RAGE have been shown to be lower in patients with metabolic syndrome. One of the possible explanations is that circulating RAGE may function as a decoy or a natural inhibitor to bind to the membrane RAGE receptor, 
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Obesity and Mortality
In this study, we showed that a higher BMI is associated with a lower mortality risk, in accordance to recent studies linking (pre)obesity to significant lower mortality rates in acute HF. [31] [32] [33] However after correction for sex and age, there is a trend toward the obesity paradox, but there is no longer a significant correlation between BMI and survival rates. Still, there is a trend visible: a BMI between 25 and 35 kg/m 2 is more favorable than a normal weight. To ensure our measurement using BMI on day 1 was not overestimated by decompensation, BMI on day 4 was also used which possibly shows a more recompensated state. This did not give any significant alternative outcome. BNP and proadrenomedullin are strong predictors for (all-cause) mortality in patients with HF. 23, 34 To evaluate their prognostic value on mortality up to 180 days, graphs were drafted to plot the 7 biomarkers found to be associated with BMI separated by a BMI below and above 30 kg/ m 2 . These hazard ratios were plotted along with a P-value for interaction. There is no significant interaction between any of these biomarkers and BMI. Thus, can be concluded that levels of these biomarkers may differ in patients with a higher BMI and might need to be interpreted differently; however, their prognostic value on mortality up to 180 days does not differ.
Limitations
The main limitation of our study is its retrospective design. The second limitation in our study is the absence of underweight patients. From 2003 patients with known BMI, only 18 people were underweight. To provide more or less even groups, patients with underweight were merged with normal weight patients. Furthermore, there are predominantly male patients in our cohort. Another limitation concerns the noncommercial immunoassays of procalcitonin, proadrenomedullin, galectin-3, and ST2. These research assays have not been standardized to the commercialized assays used in research or in clinical use and the correlation of each Alere assay to the commercial assay is not fully characterized.
Conclusions
The plasma concentrations of 7 out of 48 biomarkers were either positively or negatively influenced by BMI. These findings suggest that these markers should be interpreted with caution in patients with obesity. Although concentrations may differ in patients with obesity, the prognostic value for mortality up to 180 days did not differ per biomarker in patients with a higher BMI.
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